N-Acetylcysteine Reduces the Pro-Oxidant and Inflammatory Responses during Pancreatitis and Pancreas Tumorigenesis

• Main Authors: Marie-Albane Minati (Author), Maxime Libert (Author), Hajar Dahou (Author), Patrick Jacquemin (Author), Mohamad Assi (Author)
• Format: Book
• Published: MDPI AG, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Pancreatitis, an inflammation of the pancreas, appears to be a main driver of pancreatic cancer when combined with <i>Kras</i> mutations. In this context, the exact redox mechanisms are not clearly elucidated. Herein, we treated mice expressing a <i>Kras^G12D</i> mutation in pancreatic acinar cells with cerulein to induce acute pancreatitis. In the presence of <i>Kras^G12D</i>, pancreatitis triggered significantly greater redox unbalance and oxidative damages compared to control mice expressing <i>wild-type</i> <i>Kras</i> alleles. Further analyses identified the disruption in glutathione metabolism as the main redox event occurring during pancreatitis. Compared to the <i>wild-type</i> background, <i>Kras^G12D</i>-bearing mice showed a greater responsiveness to treatment with a thiol-containing compound, N-acetylcysteine (NAC). Notably, NAC treatment increased the pancreatic glutathione pool, reduced systemic markers related to pancreatic and liver damages, limited the extent of pancreatic edema and fibrosis as well as reduced systemic and pancreatic oxidative damages. The protective effects of NAC were, at least, partly due to a decrease in the production of tumor necrosis factor-α (TNF-α) by acinar cells, which was concomitant with the inhibition of NF-κB(p65) nuclear translocation. Our data provide a rationale to use thiol-containing compounds as an adjuvant therapy to alleviate the severity of inflammation during pancreatitis and pancreatic tumorigenesis.

Item Description

10.3390/antiox10071107
2076-3921